Massachusetts-based AI biotechnology company Nimbus Therapeutics has raised USD 210 million in a private funding round co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture. The round also saw participation from existing investors Bain Capital Life Sciences and Pfizer Ventures.
The funds raised will be used to advance Nimbus Therapeutics' pipeline of drugs for various disorders, including ongoing trials of its hematopoietic progenitor kinase 1 inhibitor in solid tumors. Further, the company aims to use these proceeds to target Werner syndrome helicase and an undisclosed immune target, as well as develop novel therapies for metabolic disorders through a partnership with Eli Lilly.
The fund raise follows the company’s USD 6 billion sales of its fully-owned subsidiary, Nimbus Lakshmi, and its Tyrosine kinase 2 (TYK2) (intracellular enzyme) program to Takeda Pharmaceuticals in February 2023 .
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.